Dark

Check out our Dark Pool Levels

ADXSW
Advaxis, Inc.
stock NASDAQ

Inactive

Oct 18, 2018

0.0071USD-52.027%(-0.0077)13,876

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Sep 10, 2021

10:00AM EDT Advaxis, Inc. (ADXS), a clinical-stage biotechnology company, reported a narrower loss in the third quarter due to reduced research and development expenses. The company noted that, following the closing of the proposed merger with Biosight, it will be renamed Biosight Therapeutics and will trade on the Nasdaq Capital Market under the ticker, BSTX. RTTNews

08:38AM EDT Advaxis Q3 Loss Per Share $0.02 Vs Loss $0.09 Last Year RTTNews

Sep 3, 2021

06:41AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 6.30 A.M. EDT). RTTNews

Jul 6, 2021

07:17AM EDT Advaxis, Inc. (ADXS), a clinical-stage biotechnology company, announced Tuesday that it has entered into a definitive merger agreement with privately held pharmaceutical development company Biosight Ltd. RTTNews

06:13AM EDT Advaxis To Acquire Biosight; Will Be Renamed Biosight Therapeutics RTTNews

Apr 5, 2021

08:15AM EDT Advaxis Announces Agreement For Funding Phase 1 Clinical Study Evaluating ADXS-504 RTTNews

Nov 24, 2020

05:43AM EST What's moving these stocks in the pre-market hours today? RTTNews

Sep 29, 2020

08:42AM EDT Advaxis Adopts Limited Duration Stockholder Rights Plan RTTNews

Sep 24, 2020

08:12AM EDT Advaxis Says FDA Cleared New IND For ADXS-504 For Treatment Of Prostate Cancer RTTNews

Sep 10, 2020

09:37AM EDT Advaxis Q3 Loss/Shr $0.09 Vs Loss $1.00 Last Year RTTNews

Share